Study S001889

Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA)

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT06588296
Acronym: TOGETHER-PsA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 279
Start: 2024-09-24
Primary completion: 2025-11-18
Lead sponsor: Eli Lilly and Company
Conditions: Psoriatic Arthritis; Obesity
Interventions: DRUG:Ixekizumab; DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I1F-MC-RHDB

Registered primary outcomes

Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction [Baseline up to Week 36]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0000566	Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities. Ciancio G, Frontiers in immunology	2026	Other trial	PMID 42131335 DOI	cites ClinicalTrials.gov:NCT06588296
R0018951	Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Merola JF, Arthritis & rheumatology (Hoboken, N.J.)	2026	Randomized trial	PMID 41903163 DOI	cites ClinicalTrials.gov:NCT06588296; registry reference DERIVED:41903163
R0055156	Editorial: Exploring innovative therapies for rare inflammatory skin diseases Dennis Niebel, Frontiers in Medicine	2026	Nonrandomized study	PMID 41939760 DOI	cites ClinicalTrials.gov:NCT06588296